Krystal Biotech Inc
Research Krystal Biotech Inc (KRYS) on Bullrun: valuation model: 19.3% overvalued, market cap USD 10.54B, P/E 44.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKRYS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal19.3% overvalued
- Market capUSD 10.54B
- P/E44.6
- Financial periodQ2 2026
- RevenueUSD 119.22M
- Net incomeUSD 54.77M
- Free cash flowUSD 71.22M
- Gross margin94.6%
Valuation Snapshot
Bullrun's latest valuation model marks Krystal Biotech Inc as 19.3% overvalued; latest market cap is USD 10.54B; P/E is 44.6.
Peer valuation comparison
Latest P/E is 44.64x versus a Healthcare sector median of 24.46x (82.5% above).
Latest P/E is 44.64x versus a United States median of 24.87x (79.5% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 389.13M | USD 204.83M | USD 188.91M | 94.1% | 6.84 | USD 496.30M | USD 9.34M | USD 1.22B |
| FY2024 | USD 290.52M | USD 89.16M | USD 119.18M | 93.1% | 3 | USD 344.87M | USD 7.26M | USD 946.38M |
| FY2023 | USD 50.70M | USD 10.93M | -USD 100.60M | n/a | 0.39 | USD 358.33M | USD 8.09M | USD 778.64M |
| FY2022 | USD 0 | -USD 139.98M | -USD 153.55M | n/a | -5.49 | USD 161.90M | USD 9.13M | USD 522.23M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 10.54B | 44.6 | n/a | n/a |
| 2025 | 2025-12-31 | USD 7.20B | 36.0 | n/a | n/a |
| 2024 | 2024-12-31 | USD 4.51B | 52.4 | n/a | n/a |
| 2023 | 2023-12-29 | USD 3.50B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.04B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.76B | n/a | n/a | n/a |
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Krystal Biotech Inc overvalued or undervalued?
Bullrun's valuation model currently marks Krystal Biotech Inc as 19.3% overvalued.
What is Krystal Biotech Inc's market cap?
Krystal Biotech Inc's market capitalization is USD 10.54B.
What is Krystal Biotech Inc's P/E ratio?
Krystal Biotech Inc's price-to-earnings (P/E) ratio is 44.6.
What does Krystal Biotech Inc do?
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).